Search research articles
Contact Us
Filters
Showing results (11-20 of 22) with videos related to
Page
of 3
Sort By:
Neurodegenerative Disease Management
|
June 22, 2023
A plain language summary of what clinical studies can tell us about the safety of evobrutinib - a potential treatment for multiple sclerosis
Xavier Montalban, Daniel Wallace, Mark C Genovese, et al.
Scientific Reports
|
May 17, 2022
<sup>99m</sup>Tc-NTP 15-5 is a companion radiotracer for assessing joint functional response to sprifermin (rhFGF-18) in a murine osteoarthritis model
Arnaud Briat, Claire Jacques, Mélodie Malige, et al.
Seminars in Arthritis and Rheumatism
|
May 19, 2021
Response letter to the Editor
Philip G Conaghan, Hans Guehring, Flavie Moreau, et al.
Seminars in Arthritis and Rheumatism
|
March 22, 2021
The effects of sprifermin on symptoms and structure in a subgroup at risk of progression in the FORWARD knee osteoarthritis trial
Hans Guehring, Flavie Moreau, Benjamin Daelken, et al.
JAMA
|
October 9, 2019
Effect of Intra-Articular Sprifermin vs Placebo on Femorotibial Joint Cartilage Thickness in Patients With Osteoarthritis: The FORWARD Randomized Clinical Trial
Marc C Hochberg, Ali Guermazi, Hans Guehring, et al.
Scientific Reports
|
March 23, 2021
Serum C-reactive protein metabolite (CRPM) is associated with incidence of contralateral knee osteoarthritis
Anne-Christine Bay-Jensen, Asger Bihlet, Inger Byrjalsen, et al.
ACR Open Rheumatology
|
February 4, 2024
Safety, Tolerability, and Pharmacodynamics of the ADAMTS-5 Nanobody M6495: Two Phase 1, Single-Center, Double-Blind, Randomized, Placebo-Controlled Studies in Healthy Subjects and Patients With Osteoarthritis
Asger Reinstrup Bihlet, Torben Balchen, Kosalaram Goteti, et al.
ACR Open Rheumatology
|
December 19, 2022
Efficacy and Safety of the Bruton's Tyrosine Kinase Inhibitor Evobrutinib in Systemic Lupus Erythematosus: Results of a Phase II, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Trial
Daniel J Wallace, Thomas Dörner, David S Pisetsky, et al.
Annals of the Rheumatic Diseases
|
May 8, 2021
Long-term structural and symptomatic effects of intra-articular sprifermin in patients with knee osteoarthritis: 5-year results from the FORWARD study
Felix Eckstein, Marc C Hochberg, Hans Guehring, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)
|
March 4, 2024
Efficacy and safety results after >3.5 years of treatment with the Bruton's tyrosine kinase inhibitor evobrutinib in relapsing multiple sclerosis: Long-term follow-up of a Phase II randomised clinical trial with a cerebrospinal fluid sub-study
Xavier Montalban, Karolina Piasecka-Stryczynska, Jens Kuhle, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 22) with videos related to
Sort By:
Page
of 3
Neurodegenerative Disease Management
|
June 22, 2023
A plain language summary of what clinical studies can tell us about the safety of evobrutinib - a potential treatment for multiple sclerosis
Xavier Montalban, Daniel Wallace, Mark C Genovese, et al.
Scientific Reports
|
May 17, 2022
<sup>99m</sup>Tc-NTP 15-5 is a companion radiotracer for assessing joint functional response to sprifermin (rhFGF-18) in a murine osteoarthritis model
Arnaud Briat, Claire Jacques, Mélodie Malige, et al.
Seminars in Arthritis and Rheumatism
|
May 19, 2021
Response letter to the Editor
Philip G Conaghan, Hans Guehring, Flavie Moreau, et al.
Seminars in Arthritis and Rheumatism
|
March 22, 2021
The effects of sprifermin on symptoms and structure in a subgroup at risk of progression in the FORWARD knee osteoarthritis trial
Hans Guehring, Flavie Moreau, Benjamin Daelken, et al.
JAMA
|
October 9, 2019
Effect of Intra-Articular Sprifermin vs Placebo on Femorotibial Joint Cartilage Thickness in Patients With Osteoarthritis: The FORWARD Randomized Clinical Trial
Marc C Hochberg, Ali Guermazi, Hans Guehring, et al.
Scientific Reports
|
March 23, 2021
Serum C-reactive protein metabolite (CRPM) is associated with incidence of contralateral knee osteoarthritis
Anne-Christine Bay-Jensen, Asger Bihlet, Inger Byrjalsen, et al.
ACR Open Rheumatology
|
February 4, 2024
Safety, Tolerability, and Pharmacodynamics of the ADAMTS-5 Nanobody M6495: Two Phase 1, Single-Center, Double-Blind, Randomized, Placebo-Controlled Studies in Healthy Subjects and Patients With Osteoarthritis
Asger Reinstrup Bihlet, Torben Balchen, Kosalaram Goteti, et al.
ACR Open Rheumatology
|
December 19, 2022
Efficacy and Safety of the Bruton's Tyrosine Kinase Inhibitor Evobrutinib in Systemic Lupus Erythematosus: Results of a Phase II, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Trial
Daniel J Wallace, Thomas Dörner, David S Pisetsky, et al.
Annals of the Rheumatic Diseases
|
May 8, 2021
Long-term structural and symptomatic effects of intra-articular sprifermin in patients with knee osteoarthritis: 5-year results from the FORWARD study
Felix Eckstein, Marc C Hochberg, Hans Guehring, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)
|
March 4, 2024
Efficacy and safety results after >3.5 years of treatment with the Bruton's tyrosine kinase inhibitor evobrutinib in relapsing multiple sclerosis: Long-term follow-up of a Phase II randomised clinical trial with a cerebrospinal fluid sub-study
Xavier Montalban, Karolina Piasecka-Stryczynska, Jens Kuhle, et al.
Page
of 3